Novartis and Sudair pharma has signed a memorandum of understanding to discuss local manufacturing agreement of a big range of cancer innovative products in the kingdom of Saudi Arabia under the patronage Dr. Hisham Aljedhaee presedent of Saudi Food & Drug Authority and in presence of Mr. Ibrahim AlSwayyel deputy of SAGIA governer and his excellency Swiss ambassador Dr. Andreas Schaller and many other specialists and decision makers in the health care filed . In the agreement, Novartis will provide all technology and quality standards to SUDAIR Pharma to ensure technology transfer of these items.
Novartis as one of the international leading pharmaceutical company is keen to engage with the Saudi society and work with different governmental agencies to participate in realization of the economic transformation (NTP) National Transformation Plan and Saudi vision in the pharmaceutical sector; therefore, Novartis decided to strategically drive a long-term localization plan which include transfer of technology, Co-manufacturing agreement with different local pharma manufacturers, building capabilities, and strengthen its clinical research programs.
To be able to help more Saudi patients suffering from cancer, Novartis decided to strengthen its local presence in Saudi by exploring a strategic partnership with a well-known and specialized local Oncology manufacturing experts, which is Sudair Pharma.
More than a decade ago, Novartis AG was the first company to form a dedicated global business unit to develop and launch innovative oncology medicines.
Novartis has more than 30 Potential blockbusters in confirmatory development and more than 500 clinical trials, is inspired by patients to revolutionize the research, development and manufacturing of innovative, high quality medicines that help to improve and extend people’s lives.
Continued commitment to this early vision has grown Novartis Oncology into a global leader in oncology, hematology and rare diseases with an unmatched portfolio of products and one of the strongest and most productive pipelines in the industry.
Our 20 Current Therapies Address Critical Needs of Patients suffering from more than 25 Hematologic Disorders or Solid Tumors.